How is Thyroid Cancer that has spread to the liver treated

Treatment of Thyroid Cancer with Liver Metastases

When thyroid cancer spreads to the liver (called metastatic disease), your care team has several treatment approaches to consider. Let me walk you through how doctors typically approach this situation.

How Doctors Think About Liver Metastases

According to the NCCN Guidelines for Thyroid Carcinoma, the first critical question is whether your cancer still responds to radioactive iodine (RAI therapy). This determines which treatment pathway makes sense:

If your cancer IS iodine-responsive:

• Radioactive iodine therapy can be used to treat liver metastases that take up iodine
• Your doctor will continue thyroid hormone suppression therapy (levothyroxine) to keep TSH levels controlled
• Follow-up imaging helps assess how well the treatment is working

If your cancer is NOT iodine-responsive (called RAI-refractory disease): This opens up several other options that your oncologist may recommend.

Treatment Options for RAI-Refractory Disease

According to NCCN Guidelines, when liver metastases don't respond to radioactive iodine, doctors typically consider:

1. Systemic Therapy (Targeted Drugs)

The preferred first-line option is lenvatinib, a kinase inhibitor that blocks multiple pathways that help tumors grow. According to the NCCN Guidelines:

• Lenvatinib showed a 65% response rate in clinical trials
• Patients on lenvatinib had progression-free survival (time before cancer worsens) of 18.3 months compared to 3.6 months with placebo
• It's taken as an oral medication daily

Alternative systemic therapies include:

• Sorafenib (another kinase inhibitor, though less effective than lenvatinib based on clinical data)
• Cabozantinib (for patients who've progressed on other VEGFR-targeted therapies)
• Other kinase inhibitors like sunitinib or axitinib
• Immunotherapy options like pembrolizumab (anti-PD-1 antibody)

2. Local Therapies (Treating Specific Lesions)

If you have a limited number of liver lesions, your doctor might consider:

• Surgical resection (removing the tumor)
• Radiofrequency ablation (RFA) - using heat to destroy tumors
• Cryoablation - using extreme cold to destroy tumors
• Ethanol ablation - injecting alcohol directly into the tumor
• Embolization - blocking blood supply to the tumor

3. Combination Approaches

Your oncologist may recommend combining treatments—for example, systemic therapy plus local treatment of specific lesions.

4. Continued TSH Suppression

Regardless of which treatment you receive, NCCN Guidelines recommend continuing levothyroxine to suppress TSH levels, as this helps control thyroid cancer growth.

Important Biomarker Testing

Before starting systemic therapy, the NCCN Guidelines recommend testing your tumor for specific mutations that might respond to targeted drugs:

• BRAF mutations → may respond to BRAF inhibitors (dabrafenib/trametinib)
• RET mutations → may respond to RET inhibitors (selpercatinib or pralsetinib)
• NTRK or ALK fusions → may respond to specific inhibitors
• Tumor mutational burden (TMB) and microsatellite instability (MSI) → may predict immunotherapy response

Questions to Ask Your Oncologist

Since YOUR specific situation requires your doctor's evaluation, here are key questions to discuss:

1. Does my cancer still respond to radioactive iodine, or is it RAI-refractory? (This determines your entire treatment pathway)

2. What genetic testing has been done on my tumor, and do I have any actionable mutations? (This may open up targeted therapy options)

3. How many liver lesions do I have, and where are they located? (This affects whether local therapies are possible)

4. Would you recommend lenvatinib or another systemic therapy, and what are the expected benefits and side effects?

5. Could I be a candidate for clinical trials? (NCCN Guidelines specifically recommend enrollment in clinical trials when available)

6. If I start systemic therapy, how will we monitor whether it's working? (Usually through imaging and tumor marker blood tests)

7. What is my TSH suppression target, and how will you monitor my thyroid hormone levels?

Managing Side Effects

According to NCCN Guidelines, kinase inhibitors like lenvatinib can cause side effects including:

• High blood pressure
• Bleeding
• Liver toxicity
• Hand-foot skin reactions

However, most side effects can be managed with dose adjustments or supportive care, and many are reversible if the medication is stopped.

Key Takeaway

Treatment of thyroid cancer with liver metastases is individualized based on whether your cancer responds to radioactive iodine, how many lesions you have, your genetic testing results, and your overall health. Your oncologist will determine the most appropriate approach for YOUR specific case by considering all these factors together.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.